https://www.selleckchem.com/products/ab680.html
4 ± 15.0, group 2 + 8.3 ± 13.0 ETDRS letters; p = 0.038). During the first year, group 1 patients received less clinical examinations (group 1 6.6 ± 3.3, group 2 7.5 ± 2.1; p = 0.007) and less injections (group 1 3.6 ± 2.7, group 2 6.1 ± 2.7; p 0.001). A greater visual gain, in response to more intensive treatment during the first year, was maintained for at least 5years in group 2 subjects. Our data confirm that in a real-world setting, early intensive treatment results in satisfying long-term visual outcomes. A greater visual gain,